These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28262585)

  • 21. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma.
    Hölscher AH; Drebber U; Schmidt H; Bollschweiler E
    Ann Surg; 2014 Nov; 260(5):779-84; discussion 784-5. PubMed ID: 25379849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma.
    Spoerl S; Novotny A; Al-Batran SE; Lordick F; Thuss-Patience P; Pauligk C; Haller B; Feith M; Lorenzen S
    Eur J Cancer; 2018 Feb; 90():26-33. PubMed ID: 29272782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015.
    van der Kaaij RT; Koemans WJ; van Putten M; Snaebjornsson P; Luijten JCHBM; van Dieren JM; Cats A; Lemmens VEPP; Verhoeven RHA; van Sandick JW
    Eur J Cancer; 2020 May; 130():23-31. PubMed ID: 32171106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
    BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
    Fareed KR; Ilyas M; Kaye PV; Soomro IN; Lobo DN; Parsons SL; Madhusudan S
    Histopathology; 2009 Oct; 55(4):399-406. PubMed ID: 19817890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
    Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL
    Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.
    Hölscher AH; Bollschweiler E; Bogoevski D; Schmidt H; Semrau R; Izbicki JR
    Eur J Cancer; 2014 Nov; 50(17):2950-7. PubMed ID: 25307749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients.
    Messager M; Neofytou K; Chaudry MA; Allum WH
    Eur J Surg Oncol; 2015 Oct; 41(10):1316-23. PubMed ID: 26166786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
    Spierings LE; Lagarde SM; van Oijen MG; Gisbertz SS; Wilmink JW; Hulshof MC; Meijer SL; Anderegg MC; van Berge Henegouwen MI; van Laarhoven HW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S766-71. PubMed ID: 26350367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of clinical T2N0M0 esophageal cancer.
    Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
    Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
    Athauda A; Watkins D; Mohammed K; Chau I; Starling N; Rao S; Tait D; Aitken K; Cunningham D
    Anticancer Res; 2018 Oct; 38(10):5943-5949. PubMed ID: 30275223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemoradiotherapy for esophageal carcinoma.
    Zhang X; Watson DI; Jamieson GG; Bessell JR; Devitt PG
    Dis Esophagus; 2005; 18(2):104-8. PubMed ID: 16053485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.
    Koëter M; van der Sangen MJ; Hurkmans CW; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
    Radiat Oncol; 2015 Mar; 10():59. PubMed ID: 25884226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
    Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
    Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma.
    Cabau M; Luc G; Terrebonne E; Belleanne G; Vendrely V; Sa Cunha A; Collet D
    Am J Surg; 2013 Jun; 205(6):711-7. PubMed ID: 23422318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
    Smit JK; Muijs CT; Burgerhof JG; Paardekooper G; Timmer PR; Muller K; Woutersen D; Mul VE; Beukema JC; Hospers GA; van Dijk BA; Langendijk JA; Plukker JT
    Ann Surg Oncol; 2013 Jun; 20(6):1985-92. PubMed ID: 23274534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
    Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.